Articles by Beth Herskovits - Pharmaceutical Executive

ADVERTISEMENT

Articles by Beth Herskovits

'Old News'

Dec 20, 2006

Analysts say Times' accusatory articles on Zyprexa are nothing to get excited about.

Good News, Bad News

Dec 13, 2006

Studies show pharma has succeeded at raising disease awareness. Brand loyalty, though, has suffered.

Lifestyle Decision

Dec 13, 2006

Recent drug trials, and marketing efforts in Europe, for Acomplia indicate that Sanofi-Aventis may be seeking a life-threatening indication for its much-hyped weight-loss drug.

Clock Watchers

Dec 13, 2006

With time ticking on Lipitor's patent, Pfizer is pulling out the stops to make the best of what valuable time it has left.

Let Bygones Be Bygones

Dec 6, 2006

Pfizer, Novartis--and even Merck--are putting the past behind them, and moving forward with COX-2 innovation.

The Ripple Effect

Dec 6, 2006

Pfizer's torcetrapib blow shifts cost-cutting measures into overdrive, causing all of industry to reevaluate staffing, marketing spend, and the viability of a potential cardiovascular breakthrough.

Pure Diversification

Dec 6, 2006

Possible sale of medical nutrition unit would not mark change in business model for the diversified drug maker.

Glaxo Consolidates Professional Ad Business

Nov 29, 2006

In a pitch of holding company vs. separate agencies, IPG nabs top prescription brands from WPP.

Launching Daytrana in a Skeptical Environment

Nov 29, 2006

Shire markets ADHD patch with unbranded campaign.

ADVERTISEMENT

Click here